tabelecleucel in the treatment of ebv ptld
Published 2 years ago • 358 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
3:29
tabelecleucel for treating ebv associated ptld
-
5:42
promising therapeutic efficacy of ebv-specific t-cell immunotherapy tabelecleucel in ptld
-
2:35
tabelecleucel as an alternative treatment option in patients following transplantation
-
2:59
tabelecleucel in ebv-associated ptld
-
1:48
do all patients require maintenance therapy following allosct?
-
12:05
how to clean/change biobase hematology valves
-
2:37
operating room integration - helion ori system from baxter
-
8:51
pbmc isolation from whole blood cells using cpt tubes
-
2:10
a study investigating the incidence of treatment-emergent autoimmune cytopenias in cll
-
2:09
overview of the cll13 trial: replacing chemotherapy with venetoclax-containing regimens
-
2:55
everolimus and itacitinib in patients with hl r/r to brentuximab vedotin and checkpoint inhibitors
-
1:29
improving virus-specific t-cell therapy
-
1:45
treatment options available for patients with al amyloidosis beyond chemotherapy & transplant
-
0:53
biosimilar rituximab in the treatment of cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
1:52
evaluating surrogacy endpoints in cll clinical trials
-
1:18
epcore nhl-1: health-related qol in patients with r/r lbcl treated with subcutaneous epcoritamab
-
1:15
personalized medicine for dlbcl
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
2:22
epcore cll-1: phase i trial of epcoritamab in r/r cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll